What is the appropriate workup for memory loss in a 76-year-old patient?

Memory Loss Workup in a 76-Year-Old Patient

Begin with a structured cognitive assessment using validated instruments (MIS or MOCA if no informant available; AD8 or Alzheimer's Questionnaire if an informant is present), followed immediately by comprehensive laboratory testing and brain MRI to exclude reversible causes. 1

Initial Clinical Assessment

History Taking

• Obtain detailed cognitive symptom history focusing on specific examples rather than accepting vague terms like "memory loss," as patients may use this term to describe word-finding difficulty, inattention, or disorientation rather than true episodic memory impairment 1
• Interview patient and informant separately when possible, as diminished insight is common in cognitive impairment and perspectives often diverge 1
• Document temporal profile: onset (abrupt versus gradual), pace of decline, and whether symptoms are episodic or continuous 1
• Assess instrumental activities of daily living specifically: balancing checkbook, cooking, driving, and manipulation of electronics 1
• Review medications for anticholinergics and sedative-hypnotics that contribute to cognitive decline 1
• Screen for psychiatric conditions including depression, as symptoms often coexist with dementia 1, 2

Objective Cognitive Testing

• If informant available: Use AD8 (Ascertain Dementia 8-Item Informant Questionnaire) or Alzheimer's Questionnaire 1
• If no informant available: Use Memory Impairment Screen (MIS) or Montreal Cognitive Assessment (MOCA) 1
• Perform serial assessments at minimum 6-month intervals using the same instrument to determine trajectory (declining, stable, or improving) 1

Essential Diagnostic Testing

Laboratory Workup

Order comprehensive metabolic panel including: 1

• Thyroid function tests
• Vitamin B12 and homocysteine levels
• Complete blood count with differential
• Complete metabolic panel (calcium, magnesium, liver function tests)
• Erythrocyte sedimentation rate and C-reactive protein

Neuroimaging

• MRI of the brain is preferred (head CT only if MRI contraindicated) 1
• Structural imaging identifies vascular disease, mass lesions, hydrocephalus, and patterns of atrophy 1

Neurological Examination

• Conduct focused neurologic physical examination to assess for focal deficits, parkinsonism, or other neurological signs 1
• Evaluate cerebrovascular risk factors as vascular contributions are common at this age 1

Specialty Referral Considerations

When to Refer

Consider subspecialty referral to neurologist, geriatrician, geriatric psychiatrist, or neuropsychologist if: 1

• Diagnosis remains unclear after initial workup
• Atypical presentation or rapid progression (weeks to months rather than years) 3, 4
• Family history of early-onset dementia with negative Alzheimer's biomarkers 5
• Need for advanced biomarker testing to guide emerging disease-modifying therapies 1

Advanced Diagnostic Options

Specialty investigations may include: 1

• Neuropsychological evaluation for detailed cognitive profiling
• Volumetric MRI to assess patterns and extent of neurodegeneration
• Lumbar puncture for CSF analysis (Aβ, tau, phosphorylated tau, amyloid-tau index)
• Amyloid PET imaging (diagnostic biomarker measuring fibrillar Aβ in brain)
• Tau PET imaging (measures fibrillar tau burden)
• FDG-PET under special circumstances to distinguish Alzheimer's disease from frontotemporal lobar degeneration

Critical Pitfalls to Avoid

• Do not attribute cognitive changes solely to "normal aging" without proper evaluation, as this delays diagnosis of treatable conditions 1, 2
• Do not assume a temporal association with surgery or trauma indicates causation without thorough investigation of other etiologies 1
• Distinguish between slowly progressive dementia (years) and rapidly progressive dementia (weeks to months), as the latter requires urgent, extensive concurrent testing for reversible causes including autoimmune encephalopathies, infections, and neoplasms 4
• Recognize that delirium (impaired consciousness) differs fundamentally from dementia (intact consciousness) and indicates serious physical illness requiring immediate attention 2

Emerging Considerations

Biomarker testing is becoming increasingly relevant as disease-modifying therapies for Alzheimer's disease require confirmed presence of pathologic changes via amyloid PET or CSF analysis for treatment eligibility 1. While current guidelines do not recommend routine biomarker use in primary care, this landscape is rapidly evolving with regulatory approvals of new therapies 1.